

# A STOMP-focused evaluation of prescribing practices in one assessment and treatment unit for people with intellectual disabilities

PAINTER, Jon <a href="http://orcid.org/0000-0003-1589-4054">http://orcid.org/0000-0003-1589-4054</a>, CHIO, Winola, BLACK, Liam and NEWMAN, David

Available from Sheffield Hallam University Research Archive (SHURA) at:

https://shura.shu.ac.uk/30566/

This document is the Published Version [VoR]

# Citation:

PAINTER, Jon, CHIO, Winola, BLACK, Liam and NEWMAN, David (2022). A STOMP-focused evaluation of prescribing practices in one assessment and treatment unit for people with intellectual disabilities. Tizard Learning Disability Review. [Article]

# Copyright and re-use policy

See http://shura.shu.ac.uk/information.html

# A STOMP-focused evaluation of prescribing practices in one assessment and treatment unit for people with intellectual disabilities

Jon Painter, Winola Chio, Liam Black and David Newman

#### **Abstract**

Purpose - This study aims to understand whether psychotropic prescribing practices for people with intellectual disabilities are in keeping with best practice guidelines.

Design/methodology/approach - This service evaluation project was a retrospective analysis of routinely collected data from the care records of all 36 people with intellectual disability discharged from an intellectual disability assessment and treatment unit during the first five years of the Stop Over medicating People with Intellectual Disabilities and/or autistic people (STOMP) initiative. Data were gathered at four time points (pre-admission, discharge, 6- and 12-month follow-up) before being analysed to understand whether psychotropic prescribing differed among people with different clinical characteristics/traits/diagnoses. Changes over time were also explored to ascertain whether and how prescribing altered from admission to discharge, and over the subsequent year of community living.

Findings - Most people with intellectual disabilities left the assessment and treatment unit on fewer regular psychotropic medications and at lower doses than at admission. These optimised regimes were still apparent 12 months post-discharge, suggesting effective discharge planning and community care packages. Inpatients with severe intellectual disabilities generally received more anxiolytics and hypnotics, at higher doses. Autistic people tended to receive more psychotropics in total and at higher cumulative doses, a pattern that persisted post discharge. A third of the sample were admitted on regular anti-psychotic medications despite having no corresponding psychotic diagnosis, a proportion that remained relatively stable through discharge and into the community.

Originality/value - This study highlights subsets of the intellectual disability population at particular risk of receiving high doses of psychotropics and a feasible template for providers intending to undertake STOMP-focused evaluations.

Keywords Psychotropic, Medication, Prescribing, Intellectual disability, STOMP, Anti-psychotic Paper type Research paper

#### Background

Mental health (MH) problems are more common in people with intellectual disabilities than the general population (Buckles et al., 2013; Cooper et al., 2007; Hemmings et al., 2013). Medication can form a helpful aspect of MH care [National Institute for Health and Care Excellence (NICE), 2015, p. 23] however, even when prescribed according to best practice, psychotropic medications carry significant risks including cardiovascular disease (Mwebe and Roberts, 2019) and metabolic abnormalities (Mazereel et al., 2020). Given the already elevated prevalence of these physical comorbidities in people with intellectual disabilities (Cooper et al., 2015), this is cause for concern, particularly because these

Jon Painter is based at the Department of Nursing and Midwifery, Sheffield Hallam University - Collegiate Crescent Campus, Sheffield, UK. Winola Chio, Liam Black and David Newman are all based at the Sheffield Health and Social Care NHS Foundation Trust, Sheffield, UK.

© Jon Painter, Winola Chio, Liam Black and David Newman. Published by Emerald Publishing Limited. This article is published under the Creative Commons Attribution (CC BY 4.0) licence. Anyone may reproduce, distribute, translate and create derivative works of this article (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this licence may be seen at http:// creativecommons.org/licences/ by/4.0/legalcode

The authors would like to thank the Local STOMP Action Group and wider Learning Disability Team for their support with this

individuals are prescribed psychotropics more frequently, at higher doses, and for longer than the norm (Bowring *et al.*, 2017; Glover and Williams, 2015; McMahon *et al.*, 2020). Finally, in 2015, in England alone, 30,000–35,000 people with intellectual disabilities received these drugs each day, despite having no psychiatric diagnoses to warrant the prescription (Glover and Williams, 2015). There are a limited number of legitimate, short-term scenarios (NICE, 2015; de Kuijper and Lenderink, 2021); however, as people with intellectual disabilities are also more likely to be prescribed antipsychotics if they exhibit behaviours of concern (Bowring *et al.*, 2017), it is likely that this is an inappropriate/off-licence form of behaviour management (Royal College of Psychiatrists, 2021; de Kuijper and Lenderink, 2021; Sheehan *et al.*, 2015).

In 2015, responding to this situation, and the Winterbourne View scandal (Department of Health, 2012a, 2012b), NHS England launched a national campaign. Its aim was to raise awareness of the issue, promote non-pharmacological interventions and increase the number of people with intellectual disabilities engaged in regular medication reviews, to "Stop Over-Medicating People with a learning disability, autism or both with psychotropic medicines" (STOMP), ultimately improving the quality of life (NHS England, 2022). By 2019, Branford *et al.* argued national awareness of these issues had improved, however, overall patterns of prescribing remained unclear. More latterly, Rauf *et al.* (2021) indicated that the awareness-raising has led to tangible reductions in over-medicating people with intellectual disabilities. Reductions in prescribing are also noted by Mehta and Glover (2019) though with more caution about causality. However, identification of local exemplars (Branford *et al.*, 2019), by definition, suggests variation and the continued existence of areas of poor prescribing practice (Kiernan *et al.*,1995). These national uncertainties necessitate ongoing local scrutiny of psychotropic medication use in people with intellectual disabilities to ensure quality of life is optimised (Bowring *et al.*, 2017; da Costa *et al.*, 2021).

Therefore, the aim of this study was to understand whether local prescribing adhered to best practice guidelines by examining:

- the needs, characteristics, traits and diagnoses of the people with intellectual disabilities admitted to one assessment and treatment unit (ATU) and prescribed psychotropics;
- how psychotropic prescribing altered between admission, discharge and the following 12 months of community living; and
- whether psychotropic prescribing differed among individuals with different clinical characteristics/traits/diagnoses.

#### Method

#### **Participants**

Data were gathered from the care records of all people with intellectual disabilities discharged from an ATU (n = 36) during the first five years of STOMP. Twenty-one (58.3%) were male; 30 (83.3%) were white British and half were aged 18–30. Pre-admission accommodation was recorded for 31 (86.1%) of individuals with 13 (36.1%) admitted from their family home; 8 (22.2%) from supported living; 6 (16.7%) from residential accommodation; 2 (5.6%) from other hospitals; 1 (2.8%) from their own house and 1 (2.8%) from a friend's. The mean number of significant life events pre-admission as per the Mini PAS-ADD (Prosser *et al.*, 1998) was 1.22 (SD 1.10); the most common being; contact with the police (n = 9), serious illness/injury (n = 7), bereavement (n = 7), moving residence (n = 5), and sexual abuse (n = 5). At admission, levels of intellectual disability (ID) were skewed towards mild/moderate levels and over 40% were autistic. Half had at least one psychiatric diagnosis of which psychosis was the most common (Table 1). Median length of stay was 147 days (range 19–754).

Level of ID and presence of ASD		Autistic	Not autistic	Tota
ID diagnosis	A	-	0	40
Mild	At admission	7	6	13
	At discharge	3	9	12
Mod	At admission	1	9	10
	At discharge	3	9	12
Severe	At admission	4	3	7
	At discharge	7	2	6
ID (level unspecified)	At admission	3	2	5
	At discharge	1	0	1
Missing data	At admission	0	1	1
	At discharge	2	0	2
Psychiatric diagnoses		Yes	No	Tot
At least one psychiatric diagnosis	At admission	18	18	36
	At discharge	28	8	36
Psychotic disorder	At admission	11	25	36
.,	At discharge	14	22	36
Anxiety disorder	At admission	5	31	36
,	At discharge	6	30	36
Mood disorder	At admission	9	27	36
	At discharge	10	26	36
Psychiatric diagnoses other	At admission	4	32	36
of ornario diagnosso stroi	At discharge	8	28	36

Pre-admission, social services funded the care packages of 18 individuals at a median annual rate of £33,101 (range £11,321–£177,280). At discharge, 29 individuals were funded at a median annual rate of £112,603 (range £10,579–£274,189), a level which remained relatively stable for 12 months.

#### Procedure

With reference to the project's goals, a bespoke data set was developed. At admission, this included demographic information, significant life events, diagnoses, community care packages and psychotropic medication. At discharge, this comprised diagnoses, care packages and psychotropics. At 6- and 12-months post-discharge, care packages and psychotropics were recorded. Staff gathered these data from the records of all ATU discharges during the first five years of STOMP (December 2015 to April 2020).

Following pseudonymisation and secure electronic transfer, data were exported into SPSS version-24 (IBM, 2016), during which, it was noted that one female had three admissions and three males each had two. The remaining 32 people with intellectual disabilities each had one admission. Consequently, to create a final data set of unique patient records (n = 36), only the earliest stays were retained. The impact of this data cleansing on participants' characteristics (above) was negligible.

This project was registered by the relevant NHS Trust as service evaluation and ethically approved by Sheffield Hallam University (ID:ER25221337).

## Analysis

For each of the four timepoints, regularly prescribed psychotropics were grouped under four British National Formulary (BNF) [Joint Formulary Committee (JFC), 2021] categories. These were antipsychotics; mood stabilisers/anti-manics; anxiolytics and hypnotics; and

antidepressants; plus, a final "other regular psychotropics" category (ultimately comprising procyclidine alone). For each category, the number of medications and total percentage of maximum BNF doses were calculated. Here, the method mirrored one typically used to define high-dose antipsychotic therapy (Royal College of psychiatrists, 2014), meaning figures over 100% were possible for individuals prescribed multiple medications from the same BNF group. These category totals were subsequently summed to create overall figures for regular psychotropics. Finally, although actual usage of Pro Re Nata (PRN) psychotropics was not captured, the number prescribed at each timepoint was recorded.

To identify statistically significant differences between timepoints, descriptive statistics for each of these variables were calculated (Table 2), together with repeated measures ANOVAs with Greenhouse–Geisser correction. Where apparent, post hoc analyses with Bonferroni adjustment revealed more about the differences.

To examine prescribing differences between different diagnostic categories, one-way ANOVAs with Tukey post hoc tests were performed. Statistically significant differences in inpatient prescribing were identified on the basis of ID level, autism and psychiatric diagnoses recorded at admission. In light of improved data quality, and the dynamic nature of MH, analyses of differences in community prescribing used level of ID, autism and psychiatric diagnoses recorded at discharge. Finally, because of particular concerns regarding over-prescribing of antipsychotics, a cross-check for diagnostic indications was undertaken.

#### Results

## Prescribing patterns over time

Table 2 shows prescribing patterns for the seven medication groupings, across timepoints. Four statistically significant changes were identified.

The mean number of regularly prescribed mood-stabilisers decreased during admission, then remained constant post discharge. A repeated measures ANOVA with Greenhouse–Geisser correction determined the differences were statistically significantly between timepoints [F(1.928, 57.841) = 4.163, p = 0.022]. However, post hoc analysis did not identify any significantly different pairwise comparisons.

The mean number of regularly prescribed anxiolytics and hypnotics decreased over time. With the 12-month post-discharge mean being less than half the pre-admission mean. The mean differed significantly between timepoints [F(2.304, 69.107) = 3.697, p = 0.025]. Post hoc analysis with Bonferroni adjustment revealed differences were only statistically significant between admission and 12 months [0.452(95% CI, 0.001 to 0.902), p = 0.049].

The mean total percentage of maximum BNF doses of "other" psychotropics (i.e. procyclidine) halved during hospitalisation, before increasing slightly post discharge. These means differed significantly between timepoints [F(1.037, 29.044) = 19.822, p = <0.001]. Post hoc analysis revealed the 12-month mean differed significantly from admission: T1[85.817(95% CI, 30.80 to 140.834), p = 0.001]; discharge: T2[86.966(95% CI, 32.550 to 141.382), p = 0.001]; and 6 months: T3[86.966 (95% CI, 31.907 to 142.025), p = 0.001], respectively.

Finally, the mean number of PRN medications rose between admission and discharge, fell to six months post-discharge, then stabilised. These means differed significantly between timepoints [F(2.565, 74.392) = 3.604, p = 0.022]. Post hoc analysis revealed that the decrease was only significant from discharge to six months [0.367(95% CI, 0.049 to 0.685), p = 0.017].

# Prescribing by diagnosis

The total number of anxiolytics and hypnotics prescribed to inpatients differed significantly by level of ID, as determined by a one-way ANOVA [F(3, 30) = 4.984, p = 0.006]. Tukey

Number of   Ti (Admission)   Ti (Admission)   Sign   Ci   Ci   Ci   Ci   Ci   Ci   Ci   C	Murribar of medications   Triusborint   Name   Name   Name   Name   Name   Societically sporticant   Information   Name	I a Die Z				l					
Mumber of   17 (Admission)   36   0   1   1   15   15   15   15   15	Tit (Admission)   36	BNF category	Variable	Timepoint	~	Min.	Мах.	Mean	SD	Statistically significant changes*	Statistically significant pairwise comparisons**
Triangle colors   Telecharge	Total S, of BNF   Total Checkbridge)	otal regularly	Number of	T1 (Admission)	36	0	7	2.6	1.9		
Total % of BNF	Total % of BMF	rescribed	medications	T2 (Discharge)	36	0	9	2.3	1.4		
Total % of BNF   Tota	Total % of BNF   Total winds post	nedications		T3 (6 months post-discharge)	36	0	2	1.9	1.3		
Total % d BNF	Total % of BNE Information post-discharge)  Number of II (Admission)			T4 (12 months post-	32	0	4	1.7	1.3		
Total % clib/F   Tit Admission   35	Total % d BNF   Ti Chemistery   35			discharge)							
Total % of BNF   Tota	Mumber of Till Checkering   36 0 3875   1212   37		Total % of BNF	T1 (Admission)	32	0	378.3	127.1	98.9		
Total % of BNF   Tota	Total % of BNF   Tota		maximum doses	T2 (Discharge)	36	0	387.5	121.2	97		
Total % of BNF	Total % d BMF			T3 (6 months post-discharge)	35	0	307.1	101.4	80.2		
Number of Tiddmisson  Tiddmi	Number of 11 (Admission)   35   0   2   0.6   0.6     Total % of BNF   Total months post-decharge)   35   0   2   0.6   0.6     Total % of BNF   Total months post-decharge)   35   0   143   0.6     Total % of BNF   Total months post-decharge)   35   0   143   0.6     Total % of BNF   Total months post-decharge)   35   0   143   0.6     Total % of BNF   Total months post-decharge)   35   0   143   0.6     Total % of BNF   Total months post-decharge)   35   0   140   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   100   0.2     Total % of BNF   Total months post-decharge)   35   0   0.0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0     Total % of BNF   Total months post-decharge)   35   0   0.0			T4 (12 months post-	30	0	350	90.1	102.9		
Number of medications         Ti (Admission)         35         0         2         0.8         0.6           Indicated of calculations         Total % of BNF         Ti (Admission)         35         0         2         0.8         0.6           Indicated % of BNF         Ti (Admission)         35         0         2         0.8         0.6           Indicated % of BNF         Ti (Admission)         35         0         143.3         38.9         37.8         37.8           Indicated % of BNF         Ti (Admission)         35         0         141.7         33.5         37.3         41.18           Number of medications         Ti (Admission)         35         0         2         0.1         0.4         4.163.p.=0.022           Number of medications         Ti (Admission)         35         0         2         0.1         0.4         4.163.p.=0.022           Indicated % of BNF         Ti (Admission)         35         0         100         2         0.1         0.4         4.163.p.=0.022           Indicated % of BNF         Ti (Admission)         35         0         100         2         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1	Number of medications         Till (Admission)         35         0         2         0.6         0			discharge)							
medications T2 (Deschage) 36 0 2 08 0.6  Total % of BNF T1 (Admission) 35 0 2 0.8 0.6  Total % of BNF T1 (Admission) 35 0 1483 27.1 41.8  Total % of BNF T1 (Admission) 35 0 1483 27.1 41.8  Number of T1 (Admission) 35 0 141.7 31.7 37.9  Total % of BNF T1 (Admission) 35 0 140 31.7 37.9  Number of T1 (Admission) 35 0 10 0 8 1 2.9  Total % of BNF T1 (Admission) 35 0 10 0 8 1 2.9  Number of T1 (Admission) 35 0 10 0 8 1 2.9  Total % of BNF T1 (Admission) 35 0 10 0 2 0.1  Total % of BNF T1 (Admission) 35 0 10 0 2 0.1  Total % of BNF T1 (Admission) 35 0 10 0 2.3  Total % of BNF T1 (Admission) 35 0 10 0 2.3  Total % of BNF T1 (Admission) 35 0 10 0 2.3  Total % of BNF T1 (Admission) 35 0 10 0 2.3  Total % of BNF T1 (Admission) 35 0 100 22.3  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.8  Total % of BNF T1 (Admission) 35 0 100 22.9  Total % of BNF T1 (Admission) 35 0 100 22.9  Total % of BNF T1 (Admission) 35 0 100 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9  Total % of BNF T1 (Admission) 35 0 150 22.9	Total % of BNF   Total changes   Total % of BNF   Total	egularly	Number of	T1 (Admission)	35	0	ო	0.7	0.8		
Total % of BNF   Tri (Arministory)   14 (12 months post-discharge)   35   0   2   0   8   0   0   0   0   0   0   0   0	Total % of BNF   Tota	rescribed	medications	T2 (Discharge)	36	0	2	0.8	9.0		
Total % of BNF	Total % of BNF TOTAL formaths post—  Total % of	ntipsychotic		T3 (6 months post-discharge)	35	0	2	0.8	9.0		
Total % of BMF	Total % of BNF	nedications		T4 (12 months post-	32	0	Ο.	0.8	0.7		
Total % of BNF   Ti (Admission)   35   168   271   418   4	Total % of BNF   Tota			discharge)							
Total % of BNF   Tota	Mumber of Tit Chechage)   36   1433   389   376   373   37		Total % of BNF	T1 (Admission)	35	0	168.8	27.1	41.8		
Table	Total % of BNF   Tota		maximum doses	T2 (Discharge)	36	0	143.3	38.9	37.6		
Total % of BNF	Total % of BNF   Tota			T3 (6 months post-discharge)	35	0	141.7	33.5	37.3		
Number of Tit (Admission)   35   0   2   0.3   0.6   7(1928,57.841) = 1.7 (Admission)   35   0   2   0.1   0.4   4.163, p = 0.022	Number of   Tit (Arminge)   Sign   Companies   Tit (Arminge)   Sign   Companies   Compan			T4 (12 months post-	35	0	140	31.7	37.9		
Number of Ti (Admission)	Number of   T1 (Admisson)   35   0   2   0.3   0.6   F1928-57.941			discharge)							
Total % of BNF   T2 (Discharge)   36   0   2   0.1   0.4   4.163, p = 0.022	Total % of BNF   T2 (Discharge)   36   0   2   0.1   0.4   4.163.p = 0.0022     Indeed medications   T2 (Bischarge)   35   0   1.0   0.4   4.163.p = 0.0022     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   4.163.p = 0.0022     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.5     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.7     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.7     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.7     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.7     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4   0.7     Indeed softwarp   T14 (Admission)   35   0   1.0   0.4     Indeed softwarp   T14 (Admission)   35   0   0.4     Indeed softwarp   T14 (Admission)	equiariy	Number of	T1 (Admission)	35	0	2	0.3	9.0	H1.928.57.841) =	
Till (Finanths post-discharge)   Signature   Signatu	Till (months post-discharge)   Signature	rescribed mood	medications	T2 (Discharge)	36	0 0	۱ ۵	0.1	0.4	4.163.0 = 0.022	
Total % of BNF	Total % of BNF	abilising		T3 (6 months post-discharge)	32.0	C	۱۵	0.1	. 0		
Total % of BNF   Tota	Total % of BNF   Tota	edications		T4 (12 months nost-	8 6	) C	1		- a		
Total % of BNF         T1 (Admission)         35         0         100         8.1         21.9           maximum doses         T2 (Discharge)         36         0         136         5         23.1           T3 (6 months post-discharge)         35         0         136         5         26.6           Number of T4 (2 months post-discharge)         36         0         1         0.6         0.5           medications         T2 (Discharge)         36         0         1         0.4         0.5           fischarge)         36         0         1         0.4         0.5         0.5           maximum doses         T3 (6 months post-discharge)         35         0         100         29.3         34.7           nawimum doses         T2 (Discharge)         36         0         100         29.3         34.7           Number of T1 (Admission)         35         0         100         29.3         34.7           Number of T1 (Admission)         35         0         20.9         0.9         0.9           T3 (6 months post-discharge)         35         0         2         0.9         0.7           T3 (6 months post-discharge)         35         0	Total % of BNF         T1 (Admission)         35         0         100         8.1         21.9           maximum doses         T2 (Discharge)         36         0         136         5         23.1           Mumber of radications         T14 (2 months post-discharge)         35         0         1         0.6         0.5           Number of radications         T2 (Discharge)         35         0         1         0.4         0.5           Indischarge)         35         0         1         0.4         0.5         0.5           Indischarge)         35         0         1         0.4         0.5         0.5           Indischarge)         35         0         1         0.4         0.5         0.5           Indischarge)         35         0         100         2.9.3         34.7         0.5           Indischarge)         35         0         100         2.9.3         34.7         0.5           Indischarge)         35         0         100         2.9.3         34.7         0.5           Indischarge)         35         0         100         2.9.3         3.7.9         0.6           Indischarge)         35 <t< td=""><td></td><td></td><td>discharge)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>			discharge)							
maximum doses         T2 (Discharge)         36         0         136         5         23.1           T3 (6 months post-discharge)         35         0         136         7.5         26.6           Number of aischarge)         17 (Admission)         35         0         1         0.6         0.5           Number of aischarge)         17 (Admission)         36         0         1         0.4         0.5           Total % of BNF         17 (Admission)         35         0         100         29.3         34.7           maximum doses         17 (Admission)         35         0         100         29.3         34.7           maximum doses         17 (Admission)         35         0         100         28.8         40.9           Number of aischarge)         17 (Admission)         35         0         100         28.8         40.9           Number of aischarge)         18 (G months post-discharge)         35         0         100         28.9         37.9           Include signal         17 (Admission)         35         0         2         0.6         0.7         36.97. $\rho$ = 0.025           Include % of BNF         17 (Admission)         35         0         23.5	maximum doses         T2 (Discharge)         36         0         136         5         2.3.1           14 (Lamonths post-discharge)         35         0         136         7.5         26.6           Number of alsoharge)         11 (Admission)         35         0         1         0.6         0.5           Number of alsoharge)         12 (Discharge)         35         0         1         0.4         0.5           Total % of BNF         14 (Lamonths post-discharge)         35         0         1         0.4         0.5           Total % of BNF         11 (Admission)         35         0         100         29.3         34.7           maximum doses         12 (Discharge)         36         0         100         27.8         38.7           Number of alsoharge)         14 (Lamonths post-discharge)         35         0         100         27.8         37.9           Mumber of alsoharge)         12 (Discharge)         35         0         20         0         0         0           Total % of BNF         11 (Admission)         35         0         2         0         0         0         0         0         0         0         0         0         0 <td< td=""><td></td><td>Total % of BNF</td><td>T1 (Admission)</td><td>35</td><td>0</td><td>100</td><td>8.1</td><td>21.9</td><td></td><td></td></td<>		Total % of BNF	T1 (Admission)	35	0	100	8.1	21.9		
T3 (months post-discharge) 35 0 136 7.5 26.6 (see discharge) 32 0 80 3.3 14.7 (12 months post-discharge) 35 0 14.7 (12 months post-discharge) 36 0 1 0.4 0.5 (see discharge) 36 0 100 29.3 34.7 (see discharge) 36 0 100 29.3 34.7 (see discharge) 36 0 100 29.3 34.7 (see discharge) 36 0 100 29.9 37.9 (see discharge) 36 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	T3 (6 months post-discharge)   35   136   7.5   26.6   14.7   14.12 months post-discharge)   35   14.7   14.12 months post-discharge)   35   14.7   14.7   14.12 months post-discharge)   36   0   1   0.4   0.5   14.7   14.12 months post-discharge)   36   0   1   0.4   0.5   14.7   14.12 months post-discharge)   35   0   100   29.3   34.7   14.12 months post-discharge)   35   0   100   27.8   38.7   14.12 months post-discharge)   35   0   100   23.9   37.9   14.12 months post-discharge)   35   0   2   0.6   0.7   14.12 months post-discharge)   35   0   2   0.6   0.7   14.12 months post-discharge)   35   0   2   0.6   0.7   14.12 months post-discharge)   35   0   2   0.4   0.7   14.12 months post-discharge)   35   0   23.5   0.4   0.7   14.12 months post-discharge)   35   0   23.75   46.7   65.2   14.14 maximum doses   12 (Discharge)   36   0   237.5   46.7   65.2   14.14 maximum doses   12 (Discharge)   36   0   237.5   46.7   65.2   14.14 maximum doses   12 (Discharge)   36   0   150   28.7   44.14 maximum doses   13 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   13 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   13 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   13 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   14 (12 months post-discharge)   35   0   150   28.7   44.14 maximum doses   15 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   15 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   15 (6 months post-discharge)   35   0   150   28.7   44.14 maximum doses   15 (6 months post-discharge)   35   0   15		maximum doses	T2 (Discharge)	36	0	136	2	23.1		
T4 (12 months post-   Octobardes    Number of	T4 (12 months post- discharge)  Number of T1 (Admission)  medications			T3 (6 months post-discharge)	35	С	136	7.5	26.6		
Number of T1(Admission)   35	Number of medications         T1 (Admission) redications         35         0         1         0.6         0.5           Total % of BNF rotal % of BNF maximum doses         T2 (Discharge) rotal % of BNF rotal			T4 (12 months post-	32	0	08	(n)	14.7		
Number of medications         T1 (Admission)         35         0         1         0.6         0.5           medications         T2 (Discharge)         36         0         1         0.4         0.5           T4 (12 months post-discharge)         35         0         1         0.4         0.5           T4 (12 months post-discharge)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           Number of discharge)         14 (12 months post-discharge)         35         0         100         23.9         37.9           Number of T1 (Admission)         35         0         2         0.9         0.8         R/2.304, 69.107) =           T2 (Discharge)         35         0         2         0.9         3.697, p = 0.025         0           T4 (12 months post-discharge)         35         0         2         0.6         0.7         0.7           I4 (12 months post-discharge)         35         0         2         0.6         0.7         0.7           I4 (12 months post-discharge)         36         0         2         0.4         0.7         0.7	Number of medications         T1 (Admission) and the post-discharge)         35         0         1         0.6         0.5           medications         T2 (Discharge) and the post-discharge)         35         0         1         0.4         0.5           T4 (12 months post-discharge) and softward of maximum doses         T1 (Admission) and the post-discharge)         35         0         100         29.3         34.7           Mumber of T4 (12 months post-discharge) and anoths post-discharge)         35         0         100         27.8         38.7           Number of T4 (12 months post-discharge) and anoths post-discharge) and anoths post-discharge)         35         0         2         0.9         0.8         40.9           Number of T4 (12 months post-discharge) and anoths post-discharge) and anoths post-discharge)         35         0         2         0.9         0.8         40.9           Total % of BNF T1 (Admission) and oses         T2 (Discharge) and anoths post-discharge) and another a			discharge)							
medications         T2 (Discharge)         36         0         1         0.4         0.5           T3 (6 months post-discharge)         35         0         1         0.4         0.5           T4 (12 months post-discharge)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           Mumber of actorarge)         T3 (6 months post-discharge)         35         0         100         28.8         40.9           Number of actorarge)         T1 (Admission)         35         0         23.9         37.9         40.9           Number of actorarge)         T2 (Discharge)         36         0         2         0.9         0.8         40.9           Number of actorarge)         T2 (Discharge)         35         0         2         0.9         0.8         40.9           T2 (Discharge)         35         0         2         0	medications         T2 (Discharge)         36         0         1         0.4         0.5           T3 (6 months post-discharge)         35         0         1         0.4         0.5           Total % of BNF         T1 (Admesion)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         20.3         34.7           maximum doses         T2 (Discharge)         35         0         100         22.8         40.9           Number of 17 (Admesion)         17 (Admesion)         35         0         20.9         0.8         AC.304, 69.107) = 0.025         0           In (In months post-discharge)         36         0         2         0.9         0.8         AC.304, 69.107) = 0.025         0           In (In months post-discharge)         35         0         2         0.9         0.8         AC.304, 69.107) = 0.025         0           In (In months post-discharge)         35         0         2         0.9         0.7         AC.304, 69.107) = 0.025         0           In (In months post-discharge)         36         0         2         0.9         0.7         0.9         0.7           I	egularly	Number of	T1 (Admission)	35	0	-	9.0	0.5		
Total % of BNF T (12 months post-discharge) 35 0 1 0.4 0.5  Tat (12 months post-discharge) 35 0 1 0.4 0.5  Total % of BNF T (14 months post-discharge) 35 0 100 29.3 34.7  Mumber of T (12 months post-discharge) 35 0 100 23.9 37.9  Number of T (14 months post-discharge) 35 0 0.8 (42.304, 69.107) = 0.025  Total % of BNF T (14 months post-discharge) 35 0 2 0.9  Total % of BNF T (14 months post-discharge) 35 0 2 0.4 0.7  Total % of BNF T (14 months post-discharge) 35 0 2 0.4  Total % of BNF T (14 months post-discharge) 35 0 2 0.4  Total % of BNF T (15 months post-discharge) 35 0 2 0.4  Total % of BNF T (15 months post-discharge) 35 0 25 0.4  Total % of BNF T (15 months post-	Total % of BNF T1 (Admission)  maximum doses  T2 (bischarge)  Number of T1 (Admission)  Total % of BNF T1 (Admission)  maximum doses  T2 (bischarge)  T3 (6 months post-discharge)  T4 (12 months post-discharge)  T4 (12 months post-discharge)  T5 (6 months post-discharge)  T6 (12 months post-discharge)  T7 (12 months post-discharge)  T6 (12 months post-discharge)  T7 (12 months post-discharge)  T6 (12 months post-discharge)  T7 (13 (6 months post-discharge)  T7 (13 (6 months post-discharge)  T8 (7 months post-discharge)  T7 (13 (6 months post-discharge)  T7 (13 (6 months post-discharge)  T8 (7 months post-discharge)  T7 (14 months post-discharge)  T8 (15 months post-discharge)  T9 (15 months post-discharge	escribed	medications	T2 (Discharge)	36	0	-	0.4	0.5		
Total % of BNF	Total % of BNF	ntidepressant		T3 (6 months post-discharge)	35	0	-	0.4	0.5		
discharge)         discharge)         35         0         100         29.3         34.7           Total % of BNF         T1 (Admission)         35         0         100         27.8         38.7           T3 (6 months post-discharge)         35         0         100         28.8         40.9           Number of discharge)         T1 (Admission)         35         0         2         0.9         0.8         RZ.304, 69.107) =           medications         T2 (Discharge)         35         0         2         0.9         3.697, p = 0.025         C           T4 (12 months post-discharge)         35         0         2         0.4         0.7         discharge)         C         0.4         0.7         discharge)         D         2         0.4         0.7         discharge)         D         2         0.4         0.7         discharge)         D         2         0.4         0.7         discharge)         D	discharge)         discharge)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           T3 (6 months post-discharge)         35         0         100         28.8         40.9           Number of discharge)         T1 (Admission)         35         0         2         0.9         3.697, p=0.025           Number of discharge)         T2 (Discharge)         35         0         2         0.9         3.697, p=0.025           Total % of BNF         T1 (Admission)         35         0         2         0.4         0.7           maximum doses         T2 (Discharge)         35         0         2         0.4         0.7           maximum doses         T2 (Discharge)         35         0         2         0.4         0.7           maximum doses         T2 (Discharge)         36         0         23.55         46.7         66.2           maximum doses         T2 (Discharge)         36         0         237.5         44.7         44	edications		T4 (12 months post-	32	0	-	0.4	0.5		
Total % of BNF         T1 (Admission)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           T3 (6 months post-discharge)         35         0         100         28.8         40.9           I 4 (12 months post-discharge)         31         0         2         0.9         0.8         RZ.304, 69.107) =           Number of discharge)         T2 (Discharge)         36         0         2         0.9         3.697, p = 0.025         C           T2 (Discharge)         35         0         2         0.4         0.7         Ad.37, p = 0.025         C           T4 (12 months post-discharge)         35         0         2         0.4         0.7         Ad.7         66.1           Total % of BNF         T1 (Admission)         35         0         2         0.4         0.7         Ad.7         66.2           maximum doses         T2 (Discharge)         36         0         46.7         66.2         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 <td>Total % of BNF         T1 (Admission)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           T3 (Emonths post-discharge)         35         0         100         27.8         38.7           Number of T1 (Admission)         35         0         2.9         37.9         40.9           medications         T1 (Admission)         36         0         2         0.9         0.8         42.304, 69.107) =           Total % of BNF         T1 (Admission)         35         0         2         0.9         0.8         42.304, 69.107) =         0           maximum doses         T2 (Discharge)         35         0         2         0.9         0.8         42.304, 69.107) =         0           Total % of BNF         T1 (Admission)         35         0         2         0.4         0.7         0           maximum doses         T2 (Discharge)         36         0         237.5         46.7         66.2           T3 (6 months post-discharge)         36         0         237.5         44.7         44</td> <td></td> <td></td> <td>discharge)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Total % of BNF         T1 (Admission)         35         0         100         29.3         34.7           maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           T3 (Emonths post-discharge)         35         0         100         27.8         38.7           Number of T1 (Admission)         35         0         2.9         37.9         40.9           medications         T1 (Admission)         36         0         2         0.9         0.8         42.304, 69.107) =           Total % of BNF         T1 (Admission)         35         0         2         0.9         0.8         42.304, 69.107) =         0           maximum doses         T2 (Discharge)         35         0         2         0.9         0.8         42.304, 69.107) =         0           Total % of BNF         T1 (Admission)         35         0         2         0.4         0.7         0           maximum doses         T2 (Discharge)         36         0         237.5         46.7         66.2           T3 (6 months post-discharge)         36         0         237.5         44.7         44			discharge)							
maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           T3 (6 months post-discharge)         35         0         100         28.8         40.9           T4 (12 months post-discharge)         35         0         2         0.9         37.9           Number of T1 (Admission)         35         0         2         0.9         3.697, p = 0.025         C           T3 (6 months post-discharge)         35         0         2         0.6         0.7         Adv.7         D.7           T4 (12 months post-discharge)         35         0         2         0.4         0.7         Adv.7         D.7           Total % of BNF         T1 (Admission)         35         0         2         0.4         0.7         Adv.7         D.7           maximum doses         T2 (Discharge)         35         0         2         0.4         0.7         Adv.7         D.5           T2 (Discharge)         35         0         2         0.4         0.7         Adv.7         D.5           T2 (Discharge)         35         0         2         0.4         0.7         Adv.7         D.5           T2 (Discharge)         36	maximum doses         T2 (Discharge)         36         0         100         27.8         38.7           T3 (6 months post-discharge)         35         0         100         28.8         40.9           T4 (12 months post-discharge)         31         0         23.9         37.9           Number of discharge)         T1 (Admission)         35         0         2         0.9         RR. (2.304, 69.107) =         0           T2 (Discharge)         35         0         2         0.6         0.7         AG. (2.25)         0           T4 (12 months post-discharge)         32         0         2         0.4         0.7         AG. (2.25)         0           Total % of BNF         T1 (Admission)         35         0         150         56.1         0         7           maximum doses         T2 (Discharge)         36         0         237.5         46.7         65.2           T3 (6 months post-discharge)         35         0         150         28.7         44.4		Total % of BNF	T1 (Admission)	35	0	100	29.3	34.7		
T3 (6 months post-discharge) 35 0 100 28.8 40.9  T4 (12 months post-discharge) 31 0 100 23.9 37.9  discharge)  Number of T1 (Admission) 35 0 2 0.9 0.8 (42.304, 69.107) = 72 (Discharge) 35 0 2 0.6 0.7  T4 (12 months post-discharge) 32 0 2 0.4 0.7  discharge)  Total % of BNF T1 (Admission) 35 0 150 51.9 56.1  maximum doses T2 (Bischarge) 35 0 150 51.9 56.1  T2 (Bischarge) 35 0 150 51.9 56.1  T3 (Bischarge) 35 0 150 51.9 56.1  T3 (Bischarge) 35 0 150 51.9 56.1	T3 (6 months post-discharge)         35         0         100         28.8         40.9           T4 (12 months post-discharge)         31         0         100         23.9         37.9           discharge)         17 (Admission)         35         0         2         0.9         3.697, p=0.025         C           Mumber of T2 (Discharge)         136         0         2         0.9         3.697, p=0.025         C           T4 (12 months post-discharge)         35         0         2         0.4         0.7           discharge)         17 (Admission)         35         0         150         51.9         56.1           maximum doses         12 (Discharge)         36         0         237.5         46.7         65.2           T3 (6 months post-discharge)         35         0         150         28.7         44         44		maximum doses	T2 (Discharge)	36	0	100	27.8	38.7		
T4 (12 months post- 31 0 100 23.9 37.9  Gischarge)  Number of T1 (Admission) 35 0 2 0.9 0.8 (F2.304, 69.107) = 0.025  T2 (Discharge) 35 0 2 0.4 0.7  T4 (12 months post-discharge) 35 0 2 0.4 0.7  discharge) 7.1 (Admission) 35 0 150 55.1  maximum doses T2 (Discharge) 36 0 150 56.1  T2 (Discharge) 36 0 150 56.1  T2 (Discharge) 36 0 150 56.1	T4 (12 months post-discharge)  Number of T1 (Admission)  Mumber of T2 (Discharge)  T2 (Discharge)  T3 (6 months post-discharge)  Total % of BNF T1 (Admission)  T3 (15 months post-discharge)  T4 (12 months post-discharge)  T4 (12 months post-discharge)  T5 (13 (6 months post-discharge)  T5 (14 months post-discharge)  T6 (15 months post-discharge)  T6 (15 months post-discharge)  T7 (16 months post-discharge)  T8 (6 months post-discharge)  T8 (6 months post-discharge)  T8 (6 months post-discharge)  T9 (15 months post-discharge)			T3 (6 months post-discharge)	35	0	100	28.8	40.9		
discharge)  Number of T1 (Admission) 35 0 2 0.9 0.8 (F2.304, 69.107) = 72 (Discharge) 36 0 3 0.8 0.9 3.697, p = 0.025  T3 (6 months post-discharge) 35 0 2 0.6 0.7 7 (12 months post-discharge) 35 0 2 0.4 0.7 7 (14 months post-discharge) 35 0 150 51.9 56.1 72 (Discharge) 35 0 150 51.9 56.1	Number of T1(Admission)   T2 (Discharge)   T2 (Discharge)   T2 (Discharge)   T2 (Discharge)   T3 (6 months post-discharge)   Total % of BNF			T4 (12 months post-	31	0	100	23.9	37.9		
Number of medications         T1 (Admission)         35         0         2         0.9         0.8         72.304, 69.107) =           T2 (Discharge)         36         0         3         0.8         0.9         3.697, p = 0.025         C           T3 (6 months post-discharge)         35         0         2         0.6         0.7         3.697, p = 0.025         C           T4 (12 months post-discharge)         32         0         2         0.4         0.7         0.7           discharge)         17 (Admission)         35         0         150         51.9         56.1           maximum doses         T2 (Discharge)         36         0         46.7         65.2	Number of medications         T1 (Admission)         35         0         2         0.9         0.8         R2.304, 69.107) =           medications         T2 (Discharge)         36         0         3         0.8         0.9         3.697, $\rho$ = 0.025         0           T3 (Emonths post-discharge)         35         0         2         0.4         0.7         3.697, $\rho$ = 0.025         0           Total % of BNF         T1 (Admission)         35         0         150         51.9         56.1         66.2           maximum doses         T2 (Discharge)         35         0         237.5         46.7         66.2           T3 (6 months post-discharge)         35         0         150         28.7         44			discharge)							
medications T2 (Discharge) 36 0 3 0.8 0.9 3.697, ρ = 0.025 T3 (6 months post-discharge) 35 0 2 0.6 0.7 T4 (12 months post-discharge) 32 0 2 0.4 0.7 discharge) 35 0 150 51.9 56.1 Total % of BNF T1 (Admission) 35 0 237.5 46.7 65.2	medications         T2 (Discharge)         36         0         3         0.8         0.9         3.697, $\rho$ = 0.025           T3 (6 months post-discharge)         35         0         2         0.6         0.7         0.7           T4 (12 months post-discharge)         32         0         2         0.4         0.7           discharge)         4         0.7         0.7         0.7           maximum doses         T2 (Discharge)         35         0         150         56.1           T3 (6 months post-discharge)         35         0         150         2.8.7         44	egularly	Number of	T1 (Admission)	35	0	2	6.0	0.8	R(2.304, 69.107) =	T1-T4 0.452 (95% CI, 0.001
T3 (6 months post-discharge) 35 0 2 0.6  T4 (12 months post- 32 0 2 0.4  discharge)  Total % of BNF T1 (Admission) 35 0 150 51.9 6  maximum doses T2 (Discharge) 36 0 237.5 46.7 6	T3 (6 months post-discharge) 35 0 2 0.6 T4 (12 months post-discharge) 32 0 2 0.4 discharge)  Total % of BNF T1 (Admission) 35 0 150 51.9 5 maximum doses T2 (Discharge) 36 0 150 28.7 6 T3 (6 months post-discharge) 35 0 150 28.7 2	rescribed	medications	T2 (Discharge)	36	0	ო	0.8	6.0	3.697, $p = 0.025$	0.902), $p = 0.049$
Total % of BNF T7 (Admission) 35 0 2 0.4 discharge)  Total % of BNF T7 (Admission) 35 0 150 51.9 maximum doses T2 (Discharge) 35 0 237.5 46.7	Total % of BNF T7 (12 months post-discharge)  Total wof BNF T7 (Admission) 35 0 150 51.9  maximum doses T2 (Discharge) 36 0 237.5 46.7  T3 (6 months post-discharge) 35 0 150 28.7	nxiolytic and		T3 (6 months post-discharge)	35	0	7	9.0	0.7		
discharge)         35         0         150         51.9           Total % of BNF         T1 (Admission)         36         0         237.5         46.7           maximum doses         T2 (Broothanger)         36         0         150         37.5         46.7	discharge)  Total % of BNF T1 (Admission) 35 0 150 51.9  maximum doses T2 (Discharge) 36 0 237.5 46.7  T3 (6 months post-discharge) 35 0 150 28.7	ypnotic		T4 (12 months post-	32	0	2	0.4	0.7		
11 (Admission) 35 0 150 51.9 T2 (Discharge) 36 0 46.7 T2 (Emorthace discharge) 36 0 150	11 (Admission) 35 0 150 51.9 T2 (Discharge) 36 0 237.5 46.7 T3 (6 months post-discharge) 35 0 150 28.7	edications		discharge)	ļ		!	;			
12(Discharge) 36 0 23/.5 46./	12 (Usonange) 36 0 237.5 46.7 T3 (6 months post-discharge) 35 0 150 28.7		lotal % of BNF	T1 (Admission)	32	0 (	150	51.9	56.1		
	20.7		maximum doses	12 (Discharge)	36	0 0	237.5	46.7	65.2		

(continued)

Table 2									
BNF category	Variable	Timepoint	2	Min.	Max.	Mean	SD	Statistically significant changes*	Statistically significant pairwise comparisons**
		T4 (12 months post- discharge)	32	0	200	27.9	55.8		
Other regularly	Number of	T1 (Admission)	35	0	-	0.2	0.4		
prescribed	medications	T2 (Discharge)	36	0	-	0.1	0.3		
psychotropic		T3 (6 months post-discharge)	35	0	-	0.1	0.3		
medications		T4 (12 months post-	32	0	-	0.1	0.3		
		discharge)							
	Total % of BNF	T1 (Admission)	35	0	20	5.2	12.6	H(1.037, 29.044) = 19.822,	T1-T4 85.817 (95% CI, 30.80 to
	maximum doses	T2 (Discharge)	36	0	33.3	2.8	8.5	p < 0.001	140.834), $p = 0.001$
		T3 (6 months post-discharge)	35	0	20	2.9	10.3		T2-T4 86.966 (95% CI,
		T4 (12 months post-	31	0	20	3.2	10.9		32.550 to 141.382), $p = 0.001$
		discharge)							T3-T4 86.966 (95% CI,
									31.907 to 142.025), $p = 0.001$
Pro Re Nate (PRN)	Number of	T1 (Admission)	35	0	2	9.0	0.7	H(2.565, 74.392) = 3.604,	T2-T3 0.367 (95% CI, 0.049 to
medications	medications	T2 (Discharge)	35	0	ო	0.8	0.8	p = 0.022	0.685), $p = 0.017$
		T3 (6 months post-discharge)	35	0	2	0.4	0.7		
		T4 (12 months post-	32	0	2	0.4	0.7		
		discharge)							
Notes: *Repeated measu	rres ANOVA with Greenhouse	Notes: "Repeated measures ANOVA with Greenhouse-Geisser correction. **Post hoc analysis with Bonferroni adjustment	sis with Bon	ferroni adjus	tment				

post hoc testing revealed the number of these medications prescribed at admission was higher for people with severe ID (1.67  $\pm$  0.516) than mild (0.69  $\pm$  0.855, p=0.049) or moderate (0.40  $\pm$  0.516, p=0.010). Similarly, the total percentage of maximum BNF doses of anxiolytics and hypnotics prescribed at admission also differed significantly [F(3, 30) = 4.756, p=0.008]. Post hoc testing revealed means were significantly higher for people with severe ID (87.97% $\pm$ 36.64%) than moderate (7.79% $\pm$ 12.23, p=0.016).

The total percentage of maximum BNF doses of all psychotropics regularly prescribed to people with/without an autism diagnosis at admission also differed significantly [F(1, 32) = 5.432, p = 0.026]. Here, the autism mean was 175.68% versus 98.25% for those without. Post hoc tests were not possible.

The total number of regularly prescribed psychotropics at discharge also differed significantly by autism diagnosis [F(1, 33) = 9.247, p = 0.005]. The autism mean was 3.07 versus 1.71 for those without.

As regards post-discharge prescribing by the specialist team, differences for autistic people continued. Firstly, the total percentage of maximum BNF doses of all regularly prescribed psychotropics at discharge differed significantly [F(1, 33) = 4.395, p = 0.044). The autism mean was 158.68% versus 91.57% for those without. Secondly, the total number of PRN psychotropics at six months also varied significantly [F(1, 32) = 4.163, p = 0.050]. Here, the autism mean was 0.64 versus 0.20 for those without. Finally, the total percentage of BNF maximum doses of all regularly prescribed psychotropics at 12 months was significantly different [F(1, 27) = 4.360, p = 0.046]. The mean autism percentage was 121.23% versus 52.78% for those without.

# Antipsychotic prescribing

Table 3 shows antipsychotic prescribing with/without diagnostic indication.

At admission, 26 people with intellectual disabilities (72.25%) had no psychotic diagnoses. Nonetheless, 12 were prescribed antipsychotics. This represents almost half this subset and one-third of the study's sample, a figure that remains reasonably constant across timepoints.

Considering MH more broadly, at admission, half the people with intellectual disabilities (n = 18) had no psychiatric diagnosis whatsoever but 11 (61.1%) were still prescribed antipsychotics. This equates to 30.55% of the sample. More positively, by discharge this had roughly halved (n = 6) before stabilising for the subsequent year.

Diagnostic group	Antipsychotic medication status	Admission	Discharge	Timepoint 6 months post- discharge	12-months post-discharge
At least one psychotic diagnosis recorded	Prescribed	7	13	10	9
	Not prescribed	3	1	3	3
	Missing data	0	0	1	2
No psychotic diagnoses recorded	Prescribed	12(5)	13(7)	14(12)	12(6)
	Not prescribed	13	9	8	8
	Missing data	1	0	0	2
At least one psychiatric diagnosis recorded	Prescribed	8	20	17	15
, ,	Not prescribed	10	8	10	10
	Missing data	0	0	1	3
No psychiatric diagnoses recorded	Prescribed	11(4)	6(3)	7(5)	6(4)
, ,	Not prescribed	6	2	ì	1
	Missing data	1	0	0	1

Around half of individuals admitted on antipsychotics without diagnostic indication were autistic. This proportion was similar at discharge and 12 months but, at 6 months post-discharge it was notably higher.

#### Discussion

Reassuringly, when considering change over time, most people with intellectual disabilities were discharged on fewer regular psychotropic medications and at lower doses than at admission. Arguably, this demonstrates the value of nurses, psychiatrists, psychologists, pharmacists, physician associates, speech and language therapists and occupational therapists working as a coordinated multi-disciplinary team to deliver positive behaviour support (PBS) interventions. Although we did not seek to definitively attribute reductions to PBS, in other studies (Gerrard et al., 2019) these interventions resulted in successful discontinuation of psychotropics in 60%-92% of participants. The government's bed closure programme is undoubtedly laudable; however, progress has been slow and ATUs are likely to remain for some time (Devine, 2019; Painter et al., 2017). When these types of interventions are eventually routinely delivered in the community, it will be important to ensure this level of coordinated PBS is retained. It is also encouraging to see that, in general, medication reductions were maintained over the subsequent 12 months of community living. In conjunction with the increased number and costs of care packages instigated at discharge, this suggests collaborative discharge planning was effective. This is important as, community transitions that are effectively facilitated by professionals can positively impact people's quality of life (Lennard et al., 2020).

Examining differences in prescribing patterns among sub-groups, inpatients with more severe ID tended to receive more anxiolytics and hypnotics, and at higher doses. Given that this group are less likely to be given a psychiatric diagnosis than the mild and moderate groups (Deutsch and Burket, 2021) this is somewhat counterintuitive; however, there are well-recognised complexities around diagnostic overshadowing that may be at play here. Additionally, autistic inpatients were prescribed more psychotropics in total and at higher cumulative doses. Given that no medications are marketed to "treat" autism (Murray *et al.*, 2014) this again appears anomalous but, could, in part, be related to the higher rate of comorbid MH problems in autistic people (Mannion and Leader, 2013).

Post discharge, for these autistic individuals, the difference in the mean number of psychotropic medications disappeared by 12 months; however, they continued to receive higher cumulative doses than their neurotypical counterparts and (perhaps as a consequence) be prescribed more PRN psychotropics.

Finally, considering antipsychotic prescribing specifically, there was a slight increase across time which was not statistically significance but of course may still be clinically significant. Furthermore, mirroring other studies (Perry et al., 2018), a concerning proportion of people with intellectual disabilities were admitted on antipsychotics without diagnostic indication, thus being exposed to potentially serious and unnecessary side effects (Mwebe and Roberts, 2019). Post discharge, this picture improved for individuals with no psychiatric diagnoses but remained stubbornly constant for those with non-psychotic psychiatric diagnoses (a phenomena worthy of future investigation). Also of note was the six-month post-discharge spike in the proportion of non-psychotic individuals prescribed antipsychotics who were autistic. Individual reasons were not captured; however, this is clinically intuitive given autistic people struggle to adapt to change (Alhuzimi, 2021); often exhibit behaviours of concern when stressed (Bowring et al., 2019); and are typically prescribed antipsychotics ahead of PBS (Bowring et al., 2017). The service is, therefore, currently remodelling its community provision and seeking increased resources for enhanced post-discharge MH and PBS.

As ever, there are limitations to these findings. The convenience sample was relatively small, from a single ATU and with varying levels of data completeness/quality which limit the generalisability of findings. The dose calculation method did not capture nuanced prescribing decisions, e.g. medications given for multiple reasons or reasons other than their primary indication. Analyses were statistically robust, but some data (e.g. prescription duration, use of PRN psychotropics and individuals' subjective experiences) were not captured. That said, all completed inpatient spells were included and findings chime with other studies.

#### Conclusion

STOMP has now been subsumed into the Department of Health's (2012a, 2012b) Transforming Care Programme (Branford *et al.*, 2019) with a range of deliverables. Unfortunately, progress with some aspects of this wider transformation initiative, e.g. bed closures have not matched the rhetoric (Devine, 2019; Painter *et al.*, 2017). Continued uncertainty about STOMP's national impact and geographical variations (Branford *et al.*, 2019; Mehta and Glover, 2019) makes local initiatives, such as this project, valuable primarily to provide an accurate picture of local psychotropic prescribing practices with this high-risk group, but also as a template for other providers to use when evaluating their services. Finally, it provides foundations upon which to build local understanding of user (and staff) experience as it identifies areas that warrant qualitative investigation.

#### References

Alhuzimi, T. (2021), "Stress and emotional wellbeing of parents due to change in routine for children with autism spectrum disorder (ASD) at home during COVID-19 pandemic in Saudi Arabia", *Research in Developmental Disabilities*, Vol. 108, p. 103822.

Bowring, D.L., Painter, J. and Hastings, R.P. (2019), "Prevalence of challenging behaviour in adults with intellectual disabilities, correlates, and association with mental health", *Current Developmental Disorders Reports*, Vol. 6 No. 4, pp. 173-181.

Bowring, D., Totsika, V., Hastings, R.P., Toogood, S. and McMahon, M. (2017), "Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability: a total population study", *Journal of Intellectual Disability Research*, Vol. 61 No. 6, pp. 604-617.

Branford, D., Gerrard, D., Saleem, N., Shaw, C. and Webster, A. (2019), "Stopping over-medication of people with an intellectual disability, autism or both (STOMP) in England part 2 – the story so far", *Advances in Mental Health and Intellectual Disabilities*, Vol. 13 No. 1, pp. 41-51.

Buckles, J., Luckasson, R. and Keefe, E. (2013), "A systematic review of the prevalence of psychiatric disorders in adults with intellectual disability, 2003-2010", *Journal of Mental Health Research in Intellectual Disabilities*, Vol. 6 No. 3, pp. 181-207.

Cooper, S.A., McLean, G., Guthrie, B., McConnachie, A., Mercer, S., Sullivan, F. and Morrison, J. (2015), "Multiple physical and mental health comorbidity in adults with intellectual disabilities: population-based cross-sectional analysis", *BMC Family Practice*, Vol. 16 No. 1, pp. 1-11.

Cooper, S.A., Smiley, E., Morrison, J., Williamson, A. and Allan, L. (2007), "Mental ill-health in adults with intellectual disabilities: prevalence and associated factors", *British Journal of Psychiatry*, Vol. 190 No. 1, pp. 27-35.

Da Costa, E., Adams, D., Salmeh, M., Mahmoud, O. and Yetkili, E. (2021), "Using clinical audit to improve the quality of mental healthcare services for people with learning disabilities", *Advances in Mental Health and Intellectual Disabilities*, Vol. 15 No. 4, pp. 105-118.

de Kuijper, G.M. and Lenderink, A.W. (2021), "Antipsychotic drug prescription and behavioral problems in individuals with intellectual disability", in Riederer, P., Laux, G., Nagatsu, T., Le, W. and Riederer, C. (Eds), *Neuro Psychopharmacotherapy*, Springer, Cham, doi: 10.1007/978-3-319-56015-1\_445-1.

Department of Health (2012a), "Transforming care: a national response to winterbourne view hospital – department of health review: final report", Department of Health London, available at: www.gov.uk/government/publications/winterbourne-view-hospital-department-of-health-review-and-response (accessed 26 July 2022).

Department of Health (2012b), "Transforming care: a national response to winterbourne view hospital", Department of Health review: final report. Dec 2012, available at: www.wp.dh.gov.uk/publications/files/2012/12/final-report.pdf

Deutsch, S.I. and Burket, J.A. (2021), "Psychotropic medication use for adults and older adults with intellectual disability; selective review, recommendations and future directions", *Prog Neuropsychopharmacol Biol Psychiatry*, Vol. 10 No. 104, p. 110017, doi: 10.1016/j.pnpbp.2020.110017.

Devine, D. (2019), "'I'd be astonished if we saw progress': Sir Stephen Bubb on the future of transforming care", Learning Disability Today. 12th March.

Gerrard, D., Rhodes, J., Lee, R. and Ling, J. (2019), "Using positive behavioural support (PBS) for STOMP medication challenge", *Advances in Mental Health and Intellectual Disabilities*, Vol. 13 Nos 3/4, pp. 102-112.

Glover, G. and Williams, R. (2015), "Prescribing of psychotropic drugs to people with learning disabilities and/or autism by general practitioners in England", Public Health England, London, available at: https://webarchive.nationalarchives.gov.uk/ukgwa/20160704152034/https://www.improvinghealthandlives.org.uk/publications/1248/text/css (accessed 26 July 2022).

Hemmings, C., Deb, S., Chaplin, E., Hardy, S. and Mukherjee, R. (2013), "Review of research for people with ID and mental health problems: a view from the United Kingdom", *Journal of Mental Health Research in Intellectual Disabilities*, Vol. 6 No. 2, pp. 127-158.

IBM (2016), "IBM SPSS statistics for windows", Version 24.0, IBM Corp, Armonk, New York, NY.

Joint Formulary Committee (JFC) (2021), "British national formulary", available at: https://bnf.nice.org.uk/ (accessed 26 July 2022).

Kiernan, C., Reeves, D. and Alborz, A. (1995), "The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour", *Journal of Intellectual Disability Research*, Vol. 39 No. 4, pp. 263-274.

Lennard, S., Sharpe, R., Goodey, R., Hudson, S. and Shankar, R. (2020), "Creating capable communities for people with intellectual disabilities: challenges and opportunities", *Journal of Mental Health Research in Intellectual Disabilities*, Vol. 13 No. 3, pp. 174-200, doi: 10.1080/19315864.2020.1783039.

McMahon, M., Hatton, C. and Bowring, D. (2020), "Polypharmacy and psychotropic polypharmacy in adults with intellectual disability: a cross-sectional total population study", *Journal of Intellectual Disability Research*, Vol. 64 No. 11, pp. 834-851, doi: 10.1111/jir.12775.

Mannion, A. and Leader, G. (2013), "Comorbidity in autism spectrum disorder: a literature review", *Research in Autism Spectrum Disorders*, Vol. 7 No. 12, pp. 1595-1616.

Mazereel, V., Detraux, J., Vancampfort, D., van Winkel, R. and De Hert, M. (2020), "Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness", *Frontiers in Endocrinology*, Vol. 11 No. 573479, p. 20.

Mehta, H. and Glover, G. (2019), "Psychotropic drugs and people with learning disabilities or autism", Public Health England, available at: https://webarchive.nationalarchives.gov.uk/ukgwa/20200104221957/https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-executive-summary (accessed 26 July 2022).

Mwebe, H. and Roberts, D. (2019), "Risk of cardiovascular disease in people taking psychotropic medication: a literature review", *British Journal of Mental Health Nursing*, Vol. 8 No. 3, p. 20.

Murray, M.L., Hsia, Y., Glaser, K., Simonoff, E., Murphy, D.G., Asherson, P.J., Eklund, H. and Wong, I.C. (2014), "Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care", *Psychopharmacology*, Vol. 231 No. 6, pp. 1011-1021, doi: 10.1007/s00213-013-3140-7.

National Institute for Health and Care Excellence (NICE) (2015), "Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges", [NICE Guideline No.11], available at: www.nice.org.uk/guidance/ng11 (accessed 26 July 2022).

NHS England (2022), "Stopping over medication of people with a learning disability, autism or both (STOMP)", available at: www.england.nhs.uk/learning-disabilities/improving-health/stomp/ (accessed 26 July 2022).

Painter, J., Ingham, B., Trevithick, L., Hastings, R.P. and Roy, A. (2017), "Correlates for the risk of specialist ID hospital admission for people with intellectual disabilities: development of the LDNAT inpatient index", *Tizard Learning Disability Review*, Vol. 23 No. 1, pp. 42-50.

Perry, B., Cooray, S., Mendis, J., Purandare, K., Wijeratne, A., Manjubhashini, S., Darari, M., Esan, F., Gunarantna, I., Naseem, R., Hoare, S., Chester, V., Roy, A., Devapriam, J., Alexander, R. and Kwok, H. (2018), "Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey", *Journal of Intellectual Disability Research*, Vol. 62 No. 2, pp. 140-149.

Prosser, H., Moss, S., Costello, H., Simpson, N., Patel, P. and Rowe, S. (1998), "Reliability and validity of the mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability", *Journal of Intellectual Disability Research*, Vol. 42 No. 4, pp. 264-272.

Rauf, B., Sheikh, H., Majid, H., Roy, A. and Pathania, R. (2021), "COVID-19-related prescribing challenge in intellectual disability", *British Journal of Psychiatry Open*, Vol. 7 No. 2, pp. 1-5.

Royal College of psychiatrists (2014), "Consensus statement on high-dose antipsychotic medication: CR190", available at: www.rcpsych.ac.uk/docs/default-source/members/faculties/rehabilitation-and-social-psychiatry/rehab-cr190.pdf?sfvrsn=d8397218\_4

Royal College of Psychiatrists (2021), "Position statement PS05/21: stopping the overprescribing of people with intellectual disability, autism or both (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP)", available at: www.rcpsych.ac.uk/docs/default-source/improving-care/better-mh-policy/position-statements/position-statement-ps0521-stomp-stamp.pdf?sfvrsn=684d09b3\_6

Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A. and Horsfall, L. (2015), "Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study", *BMJ*, Vol. 351, p. h4326, doi: 10.1136/bmj.h4326.

# Corresponding author

Jon Painter can be contacted at: j.painter@shu.ac.uk